Roche cancer immunotherapy Tecentriq wins EU approval

on September 23rd, 2017, 9:21am
ZURICH (Reuters) - Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.

More Health News

22 Sep 2017

Roche receives EU approval for Gazyvaro, European approval for Actemra

ZURICH (Reuters) - Roche said it has received European approval for its Actemra medication in giant cell arteritis (GCA), the Swiss drugmaker said on Friday.

21 Sep 2017

Versartis growth hormone drug fails key study, shares sink

(Reuters) - Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

Top News Videos